DÖKEN, D. N. Et Al. 2023. An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response. Cancer Immunology, Immunotherapy , vol.72, no.12 , 4065-4075.

DÖKEN, D. N., ÖZGÜL, İ., Yilmazbilek, I., Yakicier, M. C., KARACA EREK, E., & ERSON BENSAN, A. E., (2023). An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response. Cancer Immunology, Immunotherapy , vol.72, no.12, 4065-4075.

DÖKEN, DİDEM Et Al. "An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response," Cancer Immunology, Immunotherapy , vol.72, no.12, 4065-4075, 2023

DÖKEN, DİDEM N. Et Al. "An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response." Cancer Immunology, Immunotherapy , vol.72, no.12, pp.4065-4075, 2023

DÖKEN, D. N. Et Al. (2023) . "An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response." Cancer Immunology, Immunotherapy , vol.72, no.12, pp.4065-4075.

@article{article, author={DİDEM NAZ DÖKEN Et Al. }, title={An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response}, journal={Cancer Immunology, Immunotherapy}, year=2023, pages={4065-4075} }